Daniel Geffken

Daniel is the founder and managing director of Danforth Advisors. He brings more than 30 years of experience to his work for clients, ranging from start-ups to publicly traded companies with $1 billion+ market capitalizations. He has served as CFO and strategic consultant to numerous companies, including Apellis Pharmaceuticals, Cabaletta Bio, Inc., Cidara Therapeutics, Atea, Inc., Homology Medicines, Stealth Bio Therapeutics and Transkaryotic Therapies. Since 2013, he has participated in 10 initial public offering filings.

Over the course of his career, he has raised more than $1 billion in equity and debt securities for life sciences companies. Daniel holds a B.S. from The Wharton School, University of Pennsylvania, and M.B.A. from Harvard Business School.